Optimi Health Corp. (OPTH)
NASDAQ: OPTHHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
OPTH stock chart
Technical analysisKey statistics
All statistics- Market cap
- $8.65M
- EPS (TTM)
- -$1.56
- Dividend yield
- None
- 52-week range
- 1.51 – 6.40
- Day range
- 1.51 – 1.85
- Volume / Avg
- 26.03K / 43.55K
- Beta
- —
- Shares outstanding
- 5.73M
52-week range
OPTH stock today
Shares of Optimi Health (OPTH) finished lower on Nov 20 at $1.51, a drop of 13.71% or $0.24 per share, versus the S&P 500's 3.70% decline. Shares are 76.4% below their 52-week high of $6.40, set on May 20, 2026 and 0.0% above the 52-week low of $1.51, near the bottom of the past year's range. Optimi Health has posted a net loss over the last twelve months (EPS of -$1.56), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Optimi Health
Company profileOptimi Health Corp. operates as a pharmaceutical and nutraceutical drug manufacturing company in Canada. The company manufactures controlled substances including finished MDMA and psilocybin drug products, supplying them directly to authorized clinics, pharmacies, clinical trials, and partners.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Dane Stevens
- Headquarters
- Princeton, BC
- Website
- optimihealth.ca
OPTH news
All OPTH news- Optimi Health Sets 2027 Clinical Agenda; Expects First Ibogaine Capsules SoonNasdaqOPTH, BRK.B
- Optimi Health Outlines 2027 Plans for OPTI-101 Phase 2b in Major Depressive Disorder and OPTI-201 Phase 3 in PTSD; Announces Shares-for-Debt SettlementGlobeNewswire
- Optimi Health Completes MDMA Production For Phase 3 PTSD Trial And International SupplyNasdaqOPTH, WSO.B
- Optimi Health Completes MDMA Production for Phase 3 PTSD Trial in Canada, MAPS Trial in Israel and Commercial Supply in AustraliaGlobeNewswire
Optimi Health peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| CALCCalciMedica Inc. | 1.26 | +7.69% | $8.69M | vs OPTH |
| BIVIBioVie Inc. Class A | 0.80 | -12.07% | $8.58M | vs OPTH |
| LEXXLexaria Bioscience Corp. | 4.03 | -10.24% | $8.49M | vs OPTH |
| HINDVyome Holdings Inc. | 1.20 | -17.24% | $8.42M | vs OPTH |
| QNTMQuantum Biopharma Ltd. Class B Subordinate Voting Shares | 1.29 | -9.15% | $8.29M | vs OPTH |
| GDTCCytoMed Therapeutics Limited | 0.755 | -2.33% | $9.01M | vs OPTH |
| MBRXMoleculin Biotech Inc. | 7.74 | -2.40% | $8.22M | vs OPTH |
| PTNPalatin Technologies Inc. | 4.58 | -7.10% | $8.16M | vs OPTH |
Indexes, lists and sector
Optimi Health stock FAQ
What is Optimi Health's stock price today?
OPTH last traded at $1.51 as of Nov 20, 4:00 PM EST, down 13.71% on the day. Prices are delayed at least 15 minutes.
Who is Optimi Health's CEO?
Mr. Dane Stevens is the chief executive officer of Optimi Health Corp..
What is the OPTH 52-week high?
The 52-week high for OPTH is $6.40 and the 52-week low is $1.51. The stock is currently 76.4% below its high.